ZTS · NYSE
Zoetis Inc.
$80.00 -1.92 (-2.34%)
Company overview
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company serves both livestock animals, including cattle, swine, poultry, fish, and sheep, as well as companion animals such as dogs, cats, and horses. Its product portfolio includes vaccines that prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce specific immune responses; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that eliminate external and internal parasites such as fleas, ticks, and worms.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NYSE
- Market cap
- $33.1B
- Employees
- 13,800
- Headquarters
- Parsippany, NJ
- Website
- zoetis.com
- CEO
- Kristin C. Peck
- Listed
- February 1, 2013
- P/E
- 13.25
- Dividend yield
- 2.74%
Company financials
- Revenue
- $9.5B
- Gross profit
- $6.7B
- Operating income
- $3.6B
- EBITDA
- $4B
- Net income
- $2.6B
- EPS
- $6.04
- Total assets
- $15.2B
- Total debt
- $9.2B
- Gross margin
- 70.75%
- Net margin
- 27.79%
- Earnings yield
- 7.55%
Showing FY 2025
ZTS
1D
NYSE
O79.90H82.29L79.90C82.00+2.38 (+2.99%)Vol4.83M